Today Stories

Simris Group's Q1 2025 report released today, highlights a period of significant focus on advancing their ADC payload development, particularly with promising early data for their microcystin variants. While revenue has decreased, operational efficiency shows improvement. The company is actively managing its financial position through various loan agreements and is streamlining operations through the sale of the Hammenhög facility. The positive preclinical data, coupled with the emphasis on further studies and optimisation, positions the company for potential future milestones in targeted cancer therapy. The exploration of broader applications and the strength of their IP portfolio also indicate potential for diversification and long-term growth.

Lundbeck has reported a strong start to 2025, leading the company to raise its full-year financial guidance. This performance is primarily driven by significant growth in its strategic brands, particularly Rexulti® and Vyepti®, across all key geographical regions. The company is also making substantial investments in its R&D pipeline, with key late-stage assets like bexicaserin and amlenetug progressing according to plan. While overall profitability is strong, reflected in increased EBITDA margins, the company is facing higher administrative and R&D costs, as well as increased net financial expenses due to recent acquisition-related debt. Legal proceedings and environmental remediation efforts continue to be managed.

FDA’s two designations demonstrate KER-0193’s potential as a treatment for FXS Follows the successful completion of Phase 1 clinical trial Fragile X syndrome is the most common cause of inherited autism London, UK, 14 May 2025 – Kaerus Bioscience (“Kaerus” or “the Company”), a clinical stage biopharmaceutical company created by Medicxi for the development of therapeutics for rare genetic syndromes of neurodevelopment, today announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the U.S. Food and Drugs Administration (FDA). It follows the recent successful completion of a Phase 1 trial of KER-0193 in healthy volunteers, which confirmed the drug to be safe, well tolerated…

Aviva Capital Partners (“ACP”), Aviva’s in-house capital unit that invests in a range of infrastructure and real estate projects, and mixed-use developer Socius have unveiled plans for a new £1 billion development to create the world’s leading centre for cancer research and treatment in Sutton, London.  A planning application has been submitted to London Borough of Sutton for the development which will be delivered on a 12-acre site at the London Cancer Hub, adjacent to The Institute of Cancer Research, London, one of the world’s leading cancer research organisations, and The Royal Marsden NHS Foundation Trust’s Sutton site, Europe’s leading centre for cancer treatment. Working with London Borough of Sutton as the landowner, ACP and Socius plan to deliver c. 1 million sq ft of state-of-the…

France, 30 April 2025 – It is official: Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of Opella, Sanofi keeping a significant shareholding with a 48.2% stake and Bpifrance owning a 1.8% stake. Opella is stepping into its next chapter with powerful backing, and a clear mission - “Health in Your Hands” - making self-care as simple as it should be.This is not just a change of ownership. This is a bold move. As the purest and third-largest global player in the €190 billion Over-The-Counter and Vitamins, Minerals and Supplements space, Opella is set to lead in one of the most dynamic,  resilient corners of healthcare – where megatrends like aging populations, digital access, and self-care demand are rewriting the rule…

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva, a global life sciences leader, to provide customers with an integrated offering for optimized biologics production. The new offering will provide seamless access to Asimov’s CHO Edge cell line development platform, Cytiva's HyClone media and feed solutions, and Cytiva’s Fast Trak process development services. Together, these services and technologies enable the expression and development of protein biologics, including complex modalities, that hold the potential to significantly impact human health.  Alec Nielsen, co-founder and CEO of Asimov, says: “Central to this collaboration is the extensive optimization of our CHO Edge System in Cytiva’s HyClone media and feed, en…

Lund, Sweden, 24 April 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Søren Tulstrup will be stepping down from his position by mutual agreement as CEO after seven years of dedicated service to the Company. “On behalf of the Board of Directors, I would like to extend our gratitude to Søren for his leadership and significant contribution to the company during his tenure. Under his guidance, Hansa has evolved from a clinical-stage company into a commercial-stage biopharmaceutical organization, navigating both transformative progress and substantial challenges. We deeply appreciate Søren’s commitment to the Company and wish him every success in his future endeavors,” s…

In-licensing transforms Mosaic from a research and platform company to a clinical-stage oncology business Mosaic will develop proprietary, targeted combination products, supported by proprietary biomarkers, to realise the full potential of the assets As part of the agreement Astex has taken an equity stake in Mosaic Cambridge, UK, 24 April 2025 – Mosaic Therapeutics, Ltd (‘Mosaic’, or ‘the Company’) a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies for patients, today announces the in-licensing of two clinical-stage oncology programs from Astex Pharmaceuticals (‘Astex’), a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd. Mosaic has identified proprietary combinations incorporating the licensed products and their ta…

A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy as low as 11% for eligible patients.  The independent research ‘Achieving CAR T-Cell Therapy Health System Readiness: An assessment of barriers and opportunities’ by the IQVIA Institute for Human Data Science, funded by Gilead and Kite, highlights challenges across countries that can lead to uneven access to CAR T-cell therapy. The report, which assessed seven countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom), found that factors such as complex referral pathways, limited treatment centers and reimbursement challenges are hindering access to this potentially life-saving treatment for eligible patient…

Roche has announced a $50 billion investment in the United States over the next five years, aiming to create over 12,000 jobs. This strategic move is in response to potential tariffs from the Trump administration targeting Swiss pharmaceutical imports. The investment will expand manufacturing and distribution centers in Kentucky, Indiana, New Jersey, and California. New facilities include a gene therapy plant in Pennsylvania, a continuous glucose monitoring site in Indiana, a weight loss drug factory at an undisclosed location, and a cardiovascular, renal, and metabolism research center in Massachusetts. CEO Thomas Schinecker emphasized that this initiative will position Roche to export more medicines from the U.S. than it imports, reinforcing the company's commitment to U.S. innovation an…

Jeanette Rigby is Director Human Resources at Valneva Scotland Ltd Scotland’s life sciences sector is a crucial part of the nation’s economy, contributing groundbreaking innovation in areas such as biotechnology, pharmaceuticals, and vaccine manufacture. Recent data shows the sector now contributes almost £10.5bn to the Scottish economy, with life sciences exports worth £4.3bn, and the potential is building. Its strong academic foundation, coupled with a robust talent pool and the Scottish Government’s life sciences strategy, makes Scotland a prime destination for innovation and investment. However, if we are to remain competitive globally, Scottish companies must invest in their people. Read the full article here

Research and development funding has increased: Biopharma funding increased for the second consecutive year in 2024. Total large-pharma R&D spending continued to increase. Clinical trial start volumes have stabilized: Trial starts have fully returned to pre-pandemic levels. Priorities have continued to shift. Clinical program productivity has increased: Improvement in productivity was driven by a success-rate increase in Phase III trials. Cycle times are stabilizing: Enrollment duration – the largest opportunity to improve trial cycle times – stabilized in 2024 after having increased between 2021 and 2023. Inter-trial intervals now typically account for 17 months of total development time across an R&D program; this figure has improved greatly since the 2022 peak of 32 m…

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases. The candidate compound has the potential to reach patients with autoimmune diseases earlier in their treatment journey and achieve long-term disease control by reducing targeted B cell populations. Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therap…

Russell Abberley, Vice President and General Manager of Amgen UK and Ireland, has been confirmed as ABPI President-elect, having held the role on an interim basis. He will formally take up the Presidency on 13 May for a period of two years. Russell will lead the ABPI in its mission to make the UK the best place in the world to research, develop and launch the medicines and vaccines of the future. His immediate focus will remain on delivering a thriving UK life sciences ecosystem, where patients can access innovative medicines and vaccines and where the right conditions exist to attract global investment. He takes on the role at a pivotal moment, ahead of the publication of the NHS 10-Year Plan and the Life Sciences Sector Plan confident in the role that industry can play in delivering on t…

Hemopatch Sealing Hemostat with room temperature storage now available in Europe New product evolution enables direct accessibility in the operating room  Innovation is a direct result of collaborative efforts with surgeons, helping to ensure that customer needs are met and promoting enhanced patient care  VIENNA - 2025-04-10 Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of Hemopatch Sealing Hemostat with room temperature storage at a symposium in Austria. The evolution of the product optimizes accessibility in the operating room, delivering an immediate solution for surgeons to control bleeding or prevent leakage. The product is now available to order throughout Europe. "For over a decade, Hemopatch …

Researchers have reported a potential oral treatment for Alzheimer’s disease that slowed its progression over a period of at least 18 months. Developed by Singaporean company TauRx Pharmaceutics Ltd, the scientists based in Aberdeen report that hydromethylthionine mesylate (HMTM) could be the first oral treatment for Alzheimer’s disease (AD) that targets the tau protein pathology – if it is approved by regulators. The findings were revealed at leading international conference AD/PD 2025 in Vienna, which concluded on Saturday. At the event, TauRx Pharmaceuticals CEO and co-founder Professor Claude Wischik outlined work which compared results from HMTM’s recent Phase 3 trial with placebo data from closely matched subjects available from the Critical Path in AD (CPAD) Institute database, whic…

Brainomix 360 unlocks expert-level insights from universally available non-contrast CT scans, helping stroke networks expand access to life-changing treatments OXFORD, UK, and CHICAGO, USA 8th April 2025 – Brainomix, a global leader in AI-powered stroke imaging, has announced the FDA clearance of a novel and patented feature that enables physicians to assess ischemic core volume from universally available non-contrast CT (NCCT) images through the Brainomix 360 Stroke solution. The core volume feature has been studied and validated by leading US stroke centers, with results demonstrating equivalency to CT Perfusion and MRI-derived core volume assessments. This addresses a longstanding unmet need in stroke triage, enabling physicians across stroke networks to access expert-level insights t…

New facility will provide cost-effective manufacturing and clinical testing for pharma and contract research organisations of all sizes. Significant increase in technical positions at BDD helping further strengthen Scotland's life sciences workforce Glasgow, Scotland, 8 April 2025 – Leading contract research company BDD has opened its new 122m² GMP manufacturing facility at BioCity near Glasgow, following a successful inspection by the Medicines and Healthcare products Regulatory Authority (MHRA) in March 2025. Two years in the making, the development of the state-of-the-art facility was facilitated by a funding round of £2 million from existing investors led by the world’s longest running angel investment syndicate, Archangels, with Scottish Enterprise and new investor, British Business…

BioMed X Institute opens its global crowdsourcing platform to help principal investigators in biomedical research who have lost their NIH funding to find alternative project sponsors among the global pharmaceutical industry. Heidelberg, Germany, April 7th, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, has announced the launch of its XBridge Program, a fast-track initiative designed to support U.S.-based biomedical researchers impacted by the current NIH funding gaps, hiring freezes, and grant terminations. The program offers a pathway for affected principal investigators in all fields of human disease research. The aim of the program is to connect with potential new research sponsors from the pharmaceutical industry to continue their high-impa…

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces the launch of PRE-CISE, a Eurostars-funded research collaboration with Danish PreTT and TetraKit Technologies. The aim of the project is to develop a new generation of targeted alpha-therapeutics by expanding Akiram’s proprietary CD44v6-targeting antibody platform using advanced pre-targeting strategies and radiolabeling chemistry. The PRE-CISE project combines Akiram’s CD44v6-targeting antibody platform with PreTT’s expertise in pre-targeting technology and TetraKit’s radiolabeling chemistry. Using a two-step approach—where the antibody first binds to the tumor, followed by the separate delivery of a radioactive payload—the collaboration aims to unlock access to alpha-emitting radionuclid…